Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo’s Liraglutide Gets Advisory Committee Review; Is Byetta To Blame?

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA committee will discuss an NDA for the once-daily GLP-1 analogue March 2, likely pushing back the March 23 PDUFA date.
Advertisement

Related Content

Don’t Forget Injectable Insulin, Novo Nordisk Says
Don’t Forget Injectable Insulin, Novo Nordisk Says
Novo Nordisk Not Deterred By Regulatory Hurdles For Diabetes Drugs
Novo Nordisk Not Deterred By Regulatory Hurdles For Diabetes Drugs
Novo Nordisk Swaps Out Last Cancer Compound For Anti-Inflammatory
Novo Nordisk Swaps Out Last Cancer Compound For Anti-Inflammatory
Amylin, Lilly Partnership Tested By Lilly GLP-1 Project
Amylin, Lilly Partnership Tested By Lilly GLP-1 Project
Byetta Safety Concerns Could Set Roadblocks Ahead For New GLP-1s
Byetta Safety Concerns Could Set Roadblocks Ahead For New GLP-1s

Topics

Advertisement
UsernamePublicRestriction

Register

PS068439

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel